Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9374890 | 0.84 | PIK3CG (0.59) | MAPTALOX15CYP1A2LMNATHRB | |
| SCHEMBL4016091 | 0.82 | MAPT (0.56) | MAPTALOX15CYP1A2LMNATHRB | |
| SCHEMBL240344 | 0.82 | RAB9A (0.63) | MAPTALOX15CYP1A2LMNATHRB | |
| SCHEMBL22574529 | 0.80 | MAPT (0.50) | MAPTALOX15CYP1A2LMNATHRB | |
| SCHEMBL18405092 | 0.79 | MAPT (0.53) | MAPTALOX15CYP1A2LMNATHRB | |
| SCHEMBL20748550 | 0.79 | MAPT (0.53) | MAPTALOX15CYP1A2LMNATHRB | |
| SCHEMBL4025674 | 0.79 | MAPT (0.53) | MAPTALOX15CYP1A2LMNATHRB | |
| SCHEMBL21067200 | 0.79 | GAA (0.51) | MAPTALOX15LMNARAB9ASMN1; SMN2 | |
| SCHEMBL30577061 | 0.79 | GAA (0.51) | MAPTALOX15LMNARAB9ASMN1; SMN2 | |
| SCHEMBL13765046 | 0.78 | MAPT (0.51) | MAPTALOX15CYP1A2LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563877-B2 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | claimed |
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | claimed |
| US-7563877-B2 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563877-B2 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | DHPS, TET1, TET2 | MAPT 4438/4885ALOX15 2775/4885CYP1A2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.